Products

miLab™ BCM
Noul
Lab & Diagnostics
Noul's miLab™ BCM is an AI-powered, slide-based platform that automates CBC and blood morphology testing, providing rapid, lab-quality hematology results at the point of care to enhance diagnostic access and efficiency.

See all 1 product →

About Noul

Noul is a South Korea-based healthcare AI company specializing in an AI-based digital microscope platform for blood analysis. Their flagship product, miLab, is designed as a Decentralized Diagnostic Platform, making advanced diagnostics accessible to resource-limited medical facilities, clinics, and local hospitals. The system automates and digitizes the entire diagnostic workflow, from sample preparation to analysis, aiming to deliver high accuracy and speed compared to conventional methods.

For physicians, Noul’s technology offers a robust solution to enhance diagnostic capabilities, particularly in areas with limited laboratory infrastructure. The miLab device is an all-in-one, fully-automated system that integrates computer vision AI, bio-engineering, hardware, and software to process samples and provide AI-driven diagnoses. Noul is actively expanding its diagnostic applications, with current and developing products focusing on critical areas such as malaria diagnosis, general blood analysis, peripheral blood smears, and cervical cancer screening. The company’s overarching mission is to address chronic and systemic healthcare challenges globally by improving medical access to essential diagnostic testing.

Focus Areas

Malaria diagnosis Blood analysis Cervical cancer diagnosis Infectious diseases Blood-related disorders Point-of-care diagnostics AI-powered diagnostics In-vitro diagnostics

Business Intelligence

Key InvestorsFuturePlay, Korea Investment & Securities
PartnershipsCharité University Hospital (Germany), Limbach Group (Germany), Infinite Medical (US), Nihon Kohden Mexico, Biomedica, FIND (Foundation for Innovative New Diagnostics), Swiss Tropical and Public Health Institute, Swiss Malaria Group, National Malaria Control Program (Malawi), Ghana Infectious Disease Center, Center for Health System Strengthening (Ghana), University of Lagos (Nigeria), University of Notre Dame du Lac, Boston Children's Hospital, Columbia University The Earth Institute, PATH, Institut Pasteur Korea, Seoul National University Nano Systems Institute SOFT Foundry, UN Global Compact, Impact Alliance, Seegene Brazil
TechnologymiLab™ is an all-in-one, fully-automated digital microscopy platform integrating computer vision AI, biotechnology, hardware, and software engineering. It utilizes proprietary solid-state staining (NGSI) technology and on-device AI, enabling operation independent of network connectivity for point-of-care diagnostics.
FDA Clearances6 cleared products (estimated)

What Physicians Need to Know

Malaria Diagnosis
Noul's miLabu2122 MAL provides rapid (within 15 minutes) and highly accurate AI-powered malaria diagnosis, automating the entire microscopic diagnostic process from sample preparation to AI-based image analysis. It detects infection, distinguishes parasite species, and quantifies parasitemia, demonstrating 100% sensitivity and specificity in clinical validation.
Blood Analysis & Blood-Related Disorders
The miLabu2122 BCM (Blood Count and Morphology) solution offers lab-grade complete blood count (CBC) tests and morphology-based microscopic analysis from a small blood sample (~5u00b5L). It provides high-definition digital images of blood cells and pre-classification, capable of detecting subtle abnormal cells like immature granulocytes and blasts, enhancing the efficiency of expert interpretation.
Cervical Cancer Diagnosis
Noul's miLabu2122 CER automates cervical cell screening, streamlining the traditional Pap smear workflow into a single device. It performs staining, digital imaging, and AI analysis on cervical cells, classifying them according to the Bethesda system and detecting pre-cancerous and cancerous lesions within 15-20 minutes. It has been recognized by WHO-UNITAID as a top global solution.
AI-Powered & Point-of-Care Diagnostics
Noul commercialized the world's first AI-powered diagnostic lab, miLabu2122, which integrates AI, biotechnology, and compact robotics. This platform delivers lab-grade diagnostics at the point of care, providing precise results within 15-20 minutes, even in low-resource settings. Its on-device AI operates independently of network connectivity.
Key Differentiators
Noul's key differentiators include its fully automated, compact, and portable miLabu2122 platform, which offers lab-grade accuracy at the point of care. The proprietary NGSI (Next Generation Staining and Immunostaining) solid-based staining technology eliminates methanol, minimizes reagent use, and generates minimal wastewater. The on-device AI ensures consistent, high-quality diagnostics without relying on cloud infrastructure or expert microscopists, making it highly accessible and efficient.
Technology Stack
The miLabu2122 platform is built on a convergence of AI (deep learning, computer vision AI), biotechnology, and compact robotics. It utilizes Noul's patented NGSI solid-staining technology and is powered by NVIDIA Jetson for enhanced AI inference performance. The system fully integrates sample preparation, digital imaging, and AI analysis.
Physician Tip

For physicians, Noul's miLabu2122 platform offers significant advantages by enabling faster and more consistent diagnostic decisions due to its full automation and AI analysis, reducing diagnostic delays. Its high accuracy and reliability, even detecting cases missed by traditional microscopy, provide greater confidence in results. The ease of use and minimal training required for the system allow for efficient reallocation of human resources. Crucially, its decentralized, point-of-care capabilities and cloud-independent operation expand access to high-quality diagnostics in various settings, including remote or underserved areas. Physicians can also benefit from comprehensive analysis across malaria, blood disorders, and cervical cancer, with the added flexibility of remote review capabilities. The cost-effectiveness and eco-friendly staining further contribute to its appeal in modern healthcare.

Noul's miLabu2122 platform is designed as an all-in-one diagnostic solution, integrating sample preparation, digital imaging, and AI analysis within a single compact device. While the core platform is self-contained with on-device AI, its digital nature allows for potential integration with existing Electronic Health Record (EHR) systems for streamlined data management and remote review via its software viewer. Noul is actively expanding its market presence through strategic partnerships with laboratory networks and distributors globally, indicating a readiness for broader healthcare ecosystem integration.

Products by Noul

1 product in the directory

miLab™ BCM
Noul
Lab & Diagnostics
Noul's miLab™ BCM is an AI-powered, slide-based platform that automates CBC and blood morphology testing, providing rapid, lab-quality hematology results at the point of care to enhance diagnostic access and efficiency.

Reviews & Opinions

No web reviews on file yet for Noul. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Noul.

Loading videos...

Videos load interactively. If none appear, search YouTube for Noul →

View all on YouTube

Press & Coverage

Seoul Economic Daily
Noul to Supply AI Cervical Cancer Diagnostic Solution to Mexico
Noul signed a contract to supply its AI-based cervical cancer diagnostic solution, miLab CER, to Mexico, partnering with a major medical device distributor for exclusive supply of 100 units over four years. This follows a previous supply contract with Panama and is expected to expand Noul's market influence throughout Latin America.
2026-01
BioSpace
Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
Noul announced that FDA registration has been completed for its cervical cancer diagnostic cartridge miLabu2122 Cartridge CER and clearing agent SafeFixu2122 CER, fulfilling minimum regulatory requirements for U.S. market entry. The company will begin commercial shipments of miLab CER in Europe and Latin America, starting with countries where regulatory clearance has already been obtained.
2025-09
KBR
Noul wins Korean funding to push AI blood analyzer toward US FDA, Europe
Noul secured Korean government funding of 2.2 billion won ($1.6 million) over three years to support global clinical trials and regulatory filings for its AI-based blood analysis platform, miLab BCM. This funding will help the company expand into overseas diagnostics markets and pursue FDA 510(k) clearance and CE-IVDR certification.
2026-05
Digital Pathology News
Noul, Biomedica sign exclusive European deal for AI cervical cancer diagnostic solution
Noul signed an exclusive distribution agreement with Biomedica, a European medical device distributor, for its cervical cancer diagnostic solution miLab CER. This deal marks Noul's first distribution contract for this solution in Europe, aiming to expand sales across the continent.
2025-11
PR Newswire
Noul Supplies AI Diagnostic Platform miLabu2122 to Charitu00e9, Europe's Leading University Hospital
Noul announced the supply of its AI-based malaria diagnostic solution, miLabu2122, to Charitu00e9, a leading university hospital in Europe. This expands the reach of Noul's AI diagnostic platform.
2025-10
PR Newswire
Expanding Healthcare Access for Women's Health -- Noul Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026
Noul debuted its AI-based cervical cancer diagnostic solution at CES 2026, aiming to expand healthcare access for women's health. The solution utilizes AI automation for cervical cancer diagnostics.
2026-01
Noul News Archives
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025
Noul showcased its AI-powered cervical cancer cell screening technology at NVIDIA GTC 2025, highlighting its advancements in AI diagnostics.
2025-03
Noul News Archives
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
Noul published its fifth Sustainability Report, detailing its vision for growth and breakthroughs over the past decade.
2025-06

Frequently Asked Questions

Noul offers the miLabu2122 platform with specialized cartridges: miLabu2122 MAL for malaria diagnosis, miLabu2122 BCM for automated complete blood count and cell morphology analysis, and miLabu2122 CER for AI-powered cervical cancer cytology. These solutions integrate sample preparation, digital imaging, and AI analysis to provide accurate and efficient diagnostics for infectious diseases, blood-related disorders, and cancer screening.
The miLabu2122 platform is designed as a fully automated, compact, and on-device AI diagnostic system, enabling lab-grade results at the point of care within minutes. This significantly improves diagnostic accessibility, especially in low-resource settings or areas with limited infrastructure and expert personnel, by minimizing human variability and streamlining workflows.
Noul's miLabu2122 platform and its various cartridges (MAL, BCM, CER) have obtained CE-IVD marks, allowing market entry in Europe. The company also achieved MDSAP certification in November 2025 and FDA registration for its miLabu2122 Cartridge CER and clearing agent in September 2025, demonstrating adherence to international quality management and regulatory standards.
Noul has established significant partnerships with organizations like UNITAID, WHO FIND, and leading healthcare groups such as Germany's Limbach Group and European distributor Biomedica. These collaborations facilitate global clinical research, market expansion into over 28 countries, and distribution networks, enhancing the reach and support for miLabu2122 solutions worldwide.
Noul is a KOSDAQ-listed AI healthcare company with its miLabu2122 platform deployed in over 28 countries, rapidly expanding its market presence in malaria, blood analysis, and cervical cancer diagnostics. The company aims to impact one billion lives globally by continuing to innovate in blood and tissue diagnostics, focusing on sustained growth and entry into advanced markets like the United States.
Noul's AI-powered miLabu2122 systems automate the entire diagnostic process, from sample preparation to image analysis, significantly reducing human error and improving consistency. For malaria, miLabu2122 MAL provides high sensitivity and specificity by analyzing a much larger number of red blood cells than manual microscopy, while miLabu2122 BCM accurately detects subtle abnormal cells for comprehensive blood analysis.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

Healthcare Finance.AI is a company dedicated to leveraging cutting-edge artificial intelligence to optimize healthcare revenue cycles. Their goal is to improve financial outcomes for healthcare providers while simultaneously supporting the industry’s commitment to quality care and efficiency. They aim to achieve this by enhancing healthcare finance through AI innovation, demonstrating increased revenue cycle efficiency, reducing […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School is a global business school that is part of Imperial College London, a top-ranking science-based institution. Established in 2004, the school integrates business and entrepreneurship with technology. Its roots in business education trace back to 1955 with an operational research/management science course. The school is triple-crown accredited (AACSB, AMBA, EQUIS), placing […]

Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.